HC Wainwright & Co. Maintains Buy on SpringWorks Therapeutics, Lowers Price Target to $58
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Robert Burns maintains a 'Buy' rating on SpringWorks Therapeutics (NASDAQ:SWTX) but lowers the price target from $66 to $58.
November 09, 2023 | 12:49 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Despite the lowered price target from $66 to $58, HC Wainwright & Co. maintains a 'Buy' rating on SpringWorks Therapeutics.
The news is directly related to SpringWorks Therapeutics and is likely to influence investor sentiment. The 'Buy' rating is maintained, indicating continued confidence in the company's prospects. However, the lowered price target may suggest some caution about the company's future performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100